Sanofi’s $1.7B rare disease gambit; CAR-T boxed warning saga; New biotechs on Nasdaq; A seller’s market for M&A?; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Will the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks